European Studies on Burenorphine

Buprenorphine is available as a sublingual tablet formulation, and many assorted studies have been performed to determine its effectiveness in the treatment of opiate addiction.
Preliminary studies using low dose Buprenorphine (Temgesic) tablets performed in Belgium and France were the first to demonstrate its effectiveness. Elsewhere in Europe, several studies have been completed that have compared the use of high-dose buprenorphine and methadone.
The major comparison studies have been performed in Switzerland, Italy and Austria and these have confirmed the equivalence of the two agents in all outcome measures, apart from retention rates in some cases probably due to protracted induction phases)
Trials in Spain and Australia have been performed to investigate less than daily dosing, again demonstrating buprenorphines effectiveness in different dosing regimens.
Concerns about misuse/diversion of the product led to studies investigating the injection of doses ranging from 2-6 mg. Results demonstrated the well known ceiling effect of Buprenorphine, in this case maximal effect was seen at approximately the 12 mg dose level.
In summary, Buprenorphine has a wide effective dose range (2—32 mg/day), a wide safety margin, is well tolerated, is widely accepted by addicts, has only mild withdrawal and a low dependence liability, and offers flexibility in dosing.

Source: Author C.B. Chapleo, Reckitt & Colman Products Ltd, Hull, UK
Filed under: Treatment and Addiction :

Back to top of page

Powered by WordPress